HELXFranklin Genomic Advancements ETF

Grow my money6y track recordRanked #2,022 of 2,960 in this goal

Capital appreciation.

By Franklin Templeton Investments · Launched 2020

Annual Cost

0.50%

#2,576 of 5,562 · average

Fund Size

$23M

#4,262 of 5,562 · small

Return (1Y)Goal

+31.9%

Track Record

6 years

#2,059 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$13,268+32.7%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Active selection

Sector

Health care

Focus

Biotech & Genomics

What it actually holds

By weight

Concentration

Top 10 holdings = 44.8% of fundmoderately concentrated

Natera Inc

6.9%

Guardant Health Inc

6.8%

Krystal Biotech Inc

4.6%

Medpace Holdings Inc

4.4%

Insmed Inc

4.4%

Bridgebio Pharma Inc

4.0%

Alnylam Pharmaceuticals Inc

3.6%

United Therapeutics Corp

3.5%

Adaptive Biotechnologies Corp

3.3%

Samsung Biologics Co Ltd

3.3%

Asset allocation

Stocks

97.8%

Cash

2.2%

By sector

Healthcare

96.5%

Basic Materials

2.4%

Technology

1.1%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

21.4%High

Year-on-year price swings

Max drawdown

-58.7%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.19Below average

Sortino (3Y)

0.27Moderate downside risk

Where to buy

Listing

Exchange: Cboe BZX

Full fund details

Objective: Capital appreciation.
Strategy: Invests primarily in equity securities of companies focused on genomic advancements, including those involved in genetic engineering and gene therapy. Concentrates in health care industries but may invest across sectors and market caps, including emerging markets. The investment manager uses fundamental research to identify companies positioned to benefit from disruptive innovations in genomics and may sell securities based on valuation targets or deteriorating fundamentals.
Inception date: February 25, 2020
Fund family: Franklin Templeton Investments